You are here

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors

Authors

  • Yuxiang Ma Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China PubMed articlesGoogle scholar articles
  • Jinhui Xue Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China PubMed articlesGoogle scholar articles
  • Yuanyuan Zhao Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China PubMed articlesGoogle scholar articles
  • Yang Zhang Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China PubMed articlesGoogle scholar articles
  • Yan Huang Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China PubMed articlesGoogle scholar articles
  • Yunpeng Yang Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China PubMed articlesGoogle scholar articles
  • Wenfeng Fang Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China PubMed articlesGoogle scholar articles
  • Ye Guo Department of Oncology, Shanghai East Hospital,School of Medicine, Tongji University, Shanghai, China PubMed articlesGoogle scholar articles
  • Qun Li Department of Oncology, Shanghai East Hospital,School of Medicine, Tongji University, Shanghai, China PubMed articlesGoogle scholar articles
  • Xiaoxiao Ge Department of Oncology, Shanghai East Hospital,School of Medicine, Tongji University, Shanghai, China PubMed articlesGoogle scholar articles
  • Jie Sun Department of Clinical Medicine, Jiangsu Alphamab Biopharmaceuticals Co.,Ltd, Jiangsu, China PubMed articlesGoogle scholar articles
  • Bangyong Zhang Department of Clinical Operations, Jiangsu Alphamab Biopharmaceuticals Co.,Ltd, Jiangsu, China PubMed articlesGoogle scholar articles
  • Yuhan Zhang Department of Translational Medicine, YuceBio Technology Co., Ltd, Shenzhen, China PubMed articlesGoogle scholar articles
  • Jinyuan Xiao Department of Translational Medicine, YuceBio Technology Co., Ltd, Shenzhen, China PubMed articlesGoogle scholar articles
  • Li Zhang Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China PubMed articlesGoogle scholar articles
  • Hongyun Zhao Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China PubMed articlesGoogle scholar articles

Citation

Ma Y, Xue J, Zhao Y, et al
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer 2023;11:e006654. doi: 10.1136/jitc-2022-006654
Online issue publication 
June 01, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.